Drug Manufacturers - Major
Articles
-
It's No Accident That Drugs Are Expensive
Branded drugs are expensive in large part because it's expensive and risky to develop ... -
Will Immunotherapy Disrupt The Oncology Market?
Immunotherapy could radically change the treatment of cancer, and the revenue opportunities ... -
8 Stages Of New Drug Development
Understanding biotech data isn't easy. What is a clinical trial, what are the various ... -
Big Pharma Faces 'Pay For Delay' Lawsuits
Unless you follow the pharmaceutical and biotech sectors, it’s likely that you’ve ...
Definitions
Stock Analysis
-
Yet Another Failure Has Rigel Pharmaceuticals ...
Rigel sees yet another clinical failure from its pipeline. -
AstraZeneca Goes Back To The M&A Well Yet Again
AstraZeneca's acquisition of Amplimmune could pay big dividends in a decade. -
Amgen Sweetens The Bid And Secures Onyx
Amgen finalizes a value-additive deal for Onyx -
Novo Nordisk Getting Its Trial By Fire
Novo Nordisk is facing more challenges than it has in a while, but the growth remains ... -
Can Sanofi Investors Just Blame It On Rio?
Can Sanofi Investors Just Blame It On Rio? By Stephen D. Simpson, CFA Sanofi ... -
Better Margins Can't Hide Merck's Growth Challenges
Merck's near-term growth is looking weak, but margin improvements and an underestimated ...
Free Annual Reports